HSV pneumonia is a significant early complication in heart-lung transplant recipients, prompting the authors to recommend prophylactic acyclovir in seropositive patients during the first two postoperative months.
Answers are grounded in this paper and cite their sources.
Early HSV pneumonia observed after heart-lung transplant; this case series leaves open whether prophylaxis benefits seropositive recipients.
We report our experience of herpes simplex virus infection in a series of 51 recipients of heart lung transplantation (HLT). Nine patients, all of whom were seropositive for the virus preoperatively, developed HSV infection. Seven episodes of culture-proved mucocutaneous HSV infection without evidence of pulmonary involvement occurred in four patients. Six episodes of HSV pneumonia were seen in a further five patients, one of whom died. Diagnosis of HSV pneumonia was by histological appearances on transbronchial biopsy, together with culture of lung tissue or bronchoalveolar lavage. Concomitant cytomegalovirus infection occurred in four patients. All patients who developed HSV pneumonia did so within the first two postoperative months; in four patients following augmented immunosuppression. We now suggest that HLT recipients who are HSV antibody-positive should receive prophylactic acyclovir for the first two months after surgery and at times of augmented immunosuppression.
No takes yet. Share an insight, caveat, or question.
Smyth et al. (1990) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: